AnchorDx and Twist Launch Pan-Cancer Screening Product Globally

AnchorDx of Guangzhou and South San Francisco's Twist Bioscience have launched their Pan-Cancer Methylation Panel to global markets. The Pan-Cancer Panel was developed over a two-year period by AnchorDx in collaboration with Twist. It includes DNA methylation library preparation and targeted enrichment for next-gen sequencing (NGS). The panel covers 47 disease entities from The Cancer Genome Atlas and 31 cancer types such as lung, breast and colorectal cancers. The two companies will market the product globally for global cancer screening and scientific research. More details... Stock Symbol: (NSDQ: TWST) Share this with colleagues: // //